Tracked deals
9
9 tracked deals across 2022-2026.
Public Company
Healthcare
GSK
London, United Kingdom
We are uniting science, technology and talent to get ahead of disease together. GSK is a science-led healthcare company focused on pharmaceuticals, vaccines and specialty medicines.
- Focus Areas
- Pharmaceuticals, Vaccines, Specialty medicines
- Website
- www.gsk.com
Recent pace
3
3 tracked deals announced in the last 12 months.
Deal mix
Buyout
9 buyout
GSK Acquisition Volume by Year
Last 5 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
- Buyer
- GSK
- Target
- Chimagen Biosciences
- Industry
- Pharmaceuticals
- Location
- Sichuan, China
- Type
- Buyout
GSK has agreed to acquire full global rights to Chimagen Biosciences’ potential best-in-class trispecific T-cell engager program for multiple myeloma in a deal worth up to $750 million. The agreement includes an upfront payment and development and commercial milestone payments for the privately held Chimagen.
-
June 9, 2026
- Buyer
- GSK, Deerfield Management (announced as Nuvalent portfolio owner; not the acquirer)
- Target
- Nuvalent, Inc.
- Industry
- Pharmaceuticals
- Location
- Massachusetts, United States
- Type
- Buyout
GSK announced an agreement to acquire clinical-stage biopharmaceutical company Nuvalent for $10.6 billion to expand its lung cancer oncology portfolio. The deal will include three non-small cell lung cancer (NSCLC) programs, led by zidesamtinib and neladalkib, and is expected to drive revenue growth beginning in 2027.
-
January 23, 2026
- Buyer
- GSK
- Target
- RAPT Therapeutics
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GSK signed a definitive agreement to acquire RAPT Therapeutics for an aggregate equity value of about $2.2 billion, expanding its Respiratory, Immunology & Inflammation pipeline. The deal adds ozureprubart, a long-acting anti-IgE monoclonal antibody in Phase IIb development for prophylaxis of food-allergy reactions.
-
January 15, 2025
- Buyer
- GSK
- Target
- IDRx
- Industry
- Biotechnology
- Location
- United States
- Type
- Buyout
GSK has entered into an agreement to acquire IDRx, a Boston-based clinical-stage biopharmaceutical company focused on precision therapeutics for GIST. The deal includes an upfront payment of $1 billion plus a potential additional $150 million success-based regulatory milestone payment.
-
June 6, 2024
- Buyer
- GSK plc
- Target
- Elsie Biotechnologies
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GSK plc has completed the acquisition of Elsie Biotechnologies, a San Diego–based oligonucleotide-focused biotechnology company, for up to $50 million. The deal integrates Elsie's discovery, synthesis and delivery capabilities into GSK's oligonucleotide R&D platform to accelerate development of therapeutics for chronic hepatitis B, steatotic liver disease and other difficult-to-treat diseases.
-
January 9, 2024
- Buyer
- GSK plc
- Target
- Aiolos Bio, Inc.
- Industry
- Pharmaceuticals
- Location
- United States
- Type
- Buyout
GSK plc has entered an agreement to acquire Aiolos Bio, a clinical-stage biopharmaceutical company focused on unmet needs in respiratory and inflammatory conditions, for a $1 billion upfront payment and up to $400 million in success-based regulatory milestone payments. The deal gives GSK access to Aiolos’ AIO-001, a long-acting anti-TSLP monoclonal antibody (phase II-ready) intended for adult asthma and potentially additional indications.
-
April 18, 2023
- Buyer
- GSK plc
- Target
- BELLUS Health Inc.
- Industry
- Biotechnology
- Location
- Quebec, Canada
- Type
- Buyout
GSK plc entered into an agreement to acquire BELLUS Health Inc. in a cash deal valued at approximately US$2.0 billion (US$14.75 per share). The acquisition is intended to give GSK access to camlipixant, a late-stage (phase III) highly selective P2X3 antagonist for refractory chronic cough, with anticipated regulatory approval and launch in 2026 and expected EPS accretion from 2027.
-
August 16, 2022
- Buyer
- GSK plc
- Target
- Affinivax, Inc.
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Type
- Buyout
GSK plc acquired clinical-stage biopharmaceutical company Affinivax, Inc., paying $2.1 billion upfront and up to $1.2 billion in potential development milestones to gain the MAPS vaccine platform and a 24‑valent pneumococcal vaccine candidate (AFX3772) in development. The acquisition (100% of outstanding shares) expands GSK's vaccines R&D capabilities and pipeline, with AFX3772 in phase II and preparations underway for phase III.
-
April 13, 2022
- Buyer
- GlaxoSmithKline plc (GSK)
- Target
- Sierra Oncology, Inc (Sierra Oncology)
- Industry
- Biotechnology
- Location
- California, United States
- Type
- Buyout
GlaxoSmithKline plc (GSK) has entered into an agreement to acquire late-stage biopharmaceutical company Sierra Oncology, Inc. for $1.9 billion (approximately $55 per share in cash). The acquisition is intended to bring Sierra’s lead asset momelotinib—an investigational targeted therapy for myelofibrosis and anemia—into GSK’s specialty medicines portfolio.
Related Acquisition Pages
Selling a company? Get in front of buyers like GSK
Turn tracked acquisition activity into an outreach-ready buyer list.